Chimeric Therapeutics is trading 9.1% up today at A$0.05 as the stock rebounds from recent weakness in small-cap biotechnology names.
- The price action appears driven by a bounce-back in broader risk appetite and short-covering rather than any new company-specific announcements or trial updates.
- Market participants are noting a rotation into speculative healthcare following a period of sector-wide underperformance.